Company profile

Ticker
MRK
Exchange
Website
CEO
Kenneth C. Frazier
Employees
Incorporated
Location
Fiscal year end
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
IRS number
221918501

MRK stock data

(
)

Calendar

5 Nov 20
3 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Merck & Co earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
9 Nov 20 Kenneth C Frazier Common Stock Sell Dispose S No 81.7372 144,866 11.84M 411,546.063
9 Nov 20 Kenneth C Frazier Common Stock Sell Dispose S No 81.0756 135,134 10.96M 556,412.063
30 Oct 20 Mizell Steven Common Stock Payment of exercise Dispose F No 75.89 2,273 172.5K 5,351.145
30 Oct 20 Mizell Steven Common Stock Option exercise Aquire M No 75.89 4,574 347.12K 7,624.145
30 Oct 20 Mizell Steven RSU Common Stock Option exercise Dispose M No 0 4,574 0 4,575
30 Oct 20 Michael Nally Common Stock Payment of exercise Dispose F No 75.89 995 75.51K 12,407.936
30 Oct 20 Michael Nally Common Stock Option exercise Aquire M No 75.89 2,287 173.56K 13,402.936
30 Oct 20 Michael Nally RSU Common Stock Option exercise Dispose M No 0 2,287 0 2,288
30 Oct 20 Frank Clyburn Common Stock Payment of exercise Dispose F No 75.89 1,137 86.29K 82,518.801
30 Oct 20 Frank Clyburn Common Stock Option exercise Aquire M No 75.89 2,287 173.56K 83,655.801
72.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2370 2322 +2.1%
Opened positions 170 143 +18.9%
Closed positions 122 128 -4.7%
Increased positions 1041 1067 -2.4%
Reduced positions 869 829 +4.8%
13F shares
Current Prev Q Change
Total value 152.98B 143.16B +6.9%
Total shares 1.83B 1.85B -0.9%
Total puts 12.76M 11.32M +12.7%
Total calls 17.52M 14.49M +20.9%
Total put/call ratio 0.7 0.8 -6.8%
Largest owners
Shares Value Change
Vanguard 209.87M $17.41B -1.4%
BLK Blackrock 196.89M $16.33B -0.3%
STT State Street 117.03M $9.78B -1.5%
Wellington Management 44.73M $3.71B +5.7%
BAC Bank Of America 44.04M $3.65B +4.0%
Geode Capital Management 41.36M $3.42B +3.2%
Capital International Investors 38.21M $3.17B +6.0%
NTRS Northern Trust 33.74M $2.8B -0.1%
BK Bank Of New York Mellon 32.83M $2.72B +4.0%
JPM JPMorgan Chase & Co. 28.45M $2.33B +4.3%
Largest transactions
Shares Bought/sold Change
BRK.A Berkshire Hathaway Inc. - 22.4M +22.4M NEW
Nordea Investment Management Ab 9.24M -9.14M -49.7%
Capital World Investors 25.96M -7.51M -22.4%
JHG Janus Henderson 27.74M -3.86M -12.2%
Voya Investment Management 1.86M -3.71M -66.6%
AMP Ameriprise Financial 18.81M -3.28M -14.9%
Arrowstreet Capital, Limited Partnership 5.48M -3.17M -36.7%
Vanguard 209.87M -2.92M -1.4%
Nuveen Asset Management 20.14M +2.91M +16.9%
GS Goldman Sachs 7.72M -2.88M -27.1%

Financial report summary

?
Risks
  • The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
  • As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
  • Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
  • The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that have lost patent protection.
  • The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
  • The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
  • Developments following regulatory approval may adversely affect sales of the Company’s products.
  • The Company faces intense competition from lower cost generic products.
  • The Company faces intense competition from competitors’ products.
  • The Company faces continued pricing pressure with respect to its products.
  • The health care industry in the United States has been, and will continue to be, subject to increasing regulation and political action.
  • The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.
  • The uncertainty in global economic conditions together with cost-reduction measures being taken by certain governments could negatively affect the Company’s operating results.
  • The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
  • Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
  • In the past, the Company has experienced difficulties and delays in manufacturing certain of its products, including vaccines.
  • The Company may not be able to realize the expected benefits of its investments in emerging markets.
  • The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
  • The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
  • Pharmaceutical products can develop unexpected safety or efficacy concerns.
  • Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
  • Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.
  • Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
  • Product liability insurance for products may be limited, cost prohibitive or unavailable.
  • The proposed Spin-Off of NewCo may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
  • The costs to complete the proposed Spin-Off will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the Spin-Off of NewCo.
  • Following the Spin-Off, the price of shares of the Company’s common stock may fluctuate significantly.
  • There could be significant income tax liability if the Spin-Off or certain related transactions are determined to be taxable for U.S. federal income tax purposes.
  • Cautionary Factors that May Affect Future Results
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adjourned, API, Aybintio, Chairman, cleaning, colon, constituted, customary, Dean, dengue, Dunboyne, East, emerging, equivalent, ESCC, facilitate, Finland, flu, fulfilled, Glasglow, hearing, heightened, histology, hold, immunocompetent, instability, Ireland, lack, ladiratuzumab, Li, Middle, molnupiravir, parital, Perlmutter, permission, PMDA, Portugal, post, President, radically, rectum, replenish, replenishment, retiring, Roger, ruminant, Seagen, season, Seattle, serotype, slower, smaller, step, stringent, succeeded, Takeda, tiered, tucatinib, Tukysa, VelosBio, venue, Vice, visitor, Watson
Removed: ATM, begin, confirmatory, esophagogastric, half, men, parasitic, rosuvastatin, Rosuzet

Patents

GRANT
Utility
Ready to use porcine vaccine
1 Dec 20
The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens.
APP
Utility
Method and System for External Fish Parasite Monitoring In Aquaculture
26 Nov 20
A method for external fish parasite monitoring in aquaculture, comprising the steps of: —submerging a camera (52) in a sea pen containing fish, the camera having a field of view; —capturing images of the fish with the camera (52); and—identifying external fish parasite on the fish by analyzing the captured images, characterized in that a target region within the field of view of the camera (52) is illuminated from above and below with light of different intensities and/or spectral compositions.
APP
Utility
Liquid Vaccines of Live Enveloped Viruses
26 Nov 20
The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8.
APP
Utility
Substituted 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE Molecules As PCSK9 Allosteric Binders
26 Nov 20
Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
GRANT
Utility
Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
24 Nov 20
The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine.